{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:29:52Z","timestamp":1758817792466},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1294","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T23:00:36Z","timestamp":1394838036000},"page":"545-553","source":"Crossref","is-referenced-by-count":3,"title":["Estimation of Visceral Fat and Fatty Liver Disease Using Ultrasound in Patients with Diabetes"],"prefix":"10.2169","volume":"53","author":[{"given":"Yasunori","family":"Onitsuka","sequence":"first","affiliation":[{"name":"Onitsuka Internal Medicine and Gastroenterology Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminao","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30: 2940-2944, 2007.","DOI":"10.2337\/dc07-0792"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Day CP, James OFW. Steatohepatitis: a tale of two \"hits\"? Gastroenterology 114: 842-845, 1998.","DOI":"10.1016\/S0016-5085(98)70599-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 46: 63-69, 2011.","DOI":"10.1007\/s00535-010-0311-8"},{"key":"4","unstructured":"4. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 16: e165-e170, 2009."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apotosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci 120: 73-80, 2011.","DOI":"10.1042\/CS20100372"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shinkawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60: 1246-1257, 2011.","DOI":"10.2337\/db10-1338"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. The Examination Committee of Criteria for 'Obesity Disease' in Japan & Japan Society for the Study of Obesity, 2002.","DOI":"10.1253\/circj.66.987"},{"key":"8","unstructured":"8. Uchibori E, Kadoh K, Nakamura H, et al. Preperitoneal fat thickness (PFT) of patients undergoing a medical examination assessed by ultrasonography method. Analysis of Biological Samples 34: 147-150, 2011 (in Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Suzuki R, Watanabe S, Hirai Y, et al. Abdominal wall index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med 95: 309-314, 1993.","DOI":"10.1016\/0002-9343(93)90284-V"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kim SK, Kim HJ, Hur KY, et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic disease. Am J Clin Nutr 79: 593-599, 2004.","DOI":"10.1093\/ajcn\/79.4.593"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stolk RP, Meijer R, Mali W PTM, Grobbee DE, van der Graaf Y; SMART Study Group. Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference. Am J Clin Nutr 77: 857-860, 2003.","DOI":"10.1093\/ajcn\/77.4.857"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liu KH, Chan YL, Chan WB, Chan JCN, Chu CWW. Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 29: 379-384, 2006.","DOI":"10.2337\/diacare.29.02.06.dc05-1578"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ma RCW, Liu KH, Lam PM, et al. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycytic ovary syndrome. J Clin Endocrinol Metab 96: 799-807, 2011.","DOI":"10.1210\/jc.2010-1608"},{"key":"14","unstructured":"14. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology 52: 2206-2215, 2010."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Marchesini G, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet 358: 893-894, 2001.","DOI":"10.1016\/S0140-6736(01)06042-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307, 2006.","DOI":"10.1056\/NEJMoa060326"},{"key":"17","unstructured":"17. In: Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI [Internet]. Scotte. afssaps.fr, Paris, 2011 [cited 2011 Sep.27]: 1-41 (in French) Available from: http:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/b42a6bf9a1b63c3dbec7388d3914687b.pdf"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 27: 256-263, 2004.","DOI":"10.2337\/diacare.27.1.256"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kim C, Nan B, Kong S, et al. Changes in iron measures over menopause and associations with insulin resistance. J Womens Health 21: 872-877, 2012.","DOI":"10.1089\/jwh.2012.3549"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/6\/53_53.1294\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:50:31Z","timestamp":1621446631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/6\/53_53.1294\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1294","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}